Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.

Division of Oncology, Department of Medicine, Stanford University Medical Center, CA 94305, USA.
Immunotherapy (Impact Factor: 2.44). 09/2009; 1(5):809-24. DOI: 10.2217/imt.09.50
Source: PubMed

ABSTRACT Therapy for non-Hodgkin lymphoma has benefited greatly from basic science and clinical research such that chemotherapy and monoclonal antibody therapy have changed some lymphoma subtypes from uniformly lethal to curable, but the majority of lymphoma patients remain incurable. Novel therapies with less toxicity and more specific targeting of tumor cells are needed and immunotherapy is among the most promising of these. Recently completed randomized trials of idiotype vaccines and earlier-phase trials of other vaccine types have shown the ability to induce antitumor T cells and some clinical responses. More recently, trials of adoptive transfer of antitumor T cells have demonstrated techniques to increase the persistence and antitumor effect of these cells. Herein, we discuss lymphoma immunotherapy clinical trial results and what lessons can be taken to improve their effect, including the combination of vaccination and adoptive transfer in an approach we have dubbed 'immunotransplant'.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic vaccination holds potential as complementary treatment for non-Hodgkin's lymphoma (NHL). B-NHL cells are antigen-presenting cells, but they cannot elicit proper antitumor responses because they lack expression of co-stimulatory molecules. Here, we report a novel approach to design improved whole tumor cell vaccines for B-NHL. We demonstrated that Salmonella infection significantly up-regulates CD80, CD86, CD40 and MHC II expression in lymphoma cells, and that therapeutic vaccination with infected and then irradiated lymphoma cells combined with IL-2 elicits strong anti-tumor specific immunity and extended survival in lymphoma-bearing mice. This may represent the basis of an effective immunotherapy against B-NHL that could be easily translated into the clinics.
    Leukemia research 10/2012; 37(3). DOI:10.1016/j.leukres.2012.10.003 · 2.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The epitope in the frame region (FR) of the immunoglobulin heavy chain variable region (IgHV) is a potential target for lymphoma immunotherapy. Our previous work identified a FR-derived nonapeptide (QLVQSGAEV) capable of in vitro eliciting anti-lymphoma specific cytotoxic T lymphocytes (CTLs) in lymphocytes from human leukocyte antigen (HLA)-A2.1 donors. Here we used HLA-A2.1 transgenic mice and SCID (severe combined immunodeficiency) mice to confirm the ability of these specific CTLs against lymphomas. We immunized transgenic mice with nonapeptide conjugated to the adjuvant of PADRE (pan HLA DR-binding epitope). The specificity of the elicited CTLs from the immunized transgenic mice was identified by enzyme-linked immunospot (ELISpot) assay and pentamer staining. The elicited CTLs specifically attacked lymphomas with surface IgHV1 in vitro. Adoptive transfer of the CTLs to SCID mice loaded with QLVQSGAEV(+)/HLA-A2.1(+) lymphoma cells effectively inhibited tumor growth. Our results indicate that the relatively constant epitope in the IgHV FR may be useful for immunotherapy of lymphomas with the same IgHV subfamily.
    Leukemia & lymphoma 06/2011; 52(9):1795-802. DOI:10.3109/10428194.2011.577257 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Wilms' tumor antigen (WT1) is overexpressed in many different solid tumors and hematologic malignancies. However, little is known about WT1 expression or WT1-specific immune responses in patients with non-Hodgkin lymphoma (NHL). In a cross-sectional survey study, we investigated the immune recognition of WT1 by NHL patients. Utilizing a WT1 overlapping peptide library, we discovered that a large percentage of NHL patients of all grades maintain WT1-specific T cells. Ex vivo frequencies of these T cells measured from unfractionated samples by the CD137 activation marker assay were high in many patients (some >1% CD8+). Using standard in vitro techniques we discovered they were cytotoxic to WT1 peptide library-loaded T2 cells and WT1 antigen-primed autologous EBV-transformed B cell lines (EBV-LCL) and expressed interferon gamma (IFN-γ). In addition, we detected WT1 mRNA transcripts in diseased lymph node tissues of NHL patients utilizing real-time quantitative polymerase chain reaction (RT-qPCR) technology. These results are the first example of strong T cell reactivity against WT1 in NHL patients which also demonstrate strong cytotoxicity against peptide-loaded tumor cells. The potential for developing WT1 as a target for immunotherapy in NHL deserves further exploration.
    Leukemia & lymphoma 03/2013; 54(11). DOI:10.3109/10428194.2013.783910 · 2.61 Impact Factor